Considering both tumor- and liver function-related factors, the hepatoma arterial-embolization prognostic (HAP) score (including tumor size, bilirubin, albumin, and α-fetoprotein (AFP)) has exhibited a promising prediction performance in uHCC patients following TACE (17–20). The gene discussed is AFP; the disease is hepatocellular carcinoma.